-
1.发明申请公开(公告)号：US20200370130A1
公开(公告)日：2020-11-26
申请号：US16959806
申请日：2019-01-04
申请人： VISIONGATE, INC.
发明人： Daniel J. Sussman , Michael Meyer G. Meyer , Laimonis Kelbauskas , Alan C. Nelson , Randall Mastrangelo
IPC分类号： C12Q1/6886 , G16B20/50 , G16B40/20
摘要： A method to develop one or more morphometric classifiers to identify a tumor mutation burden (TMB). The method provides a non-invasive method of characterizing TMB that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.
-
公开(公告)号：US11069054B2
公开(公告)日：2021-07-20
申请号：US15403940
申请日：2017-01-11
申请人： VISIONGATE, INC.
IPC分类号： A61K31/167 , G06T7/00 , G01N33/483 , A61K31/5578 , A61K31/593 , G01N15/14 , G06K9/00 , G01N15/10
摘要： A method of treating a malignancy in a human subject by analyzing pseudo-projection images of cells obtained from a sputum specimen obtained from a subject employs a biological specimen classifier that identifies cells from the sputum specimen as normal or abnormal. If abnormal cells are detected, then the abnormal cells are further classified as dysplastic or cancerous. If the cells are classified as dysplastic, then an immunomodulating agent is administered to the subject over a predetermined time period designed to achieve a therapeutic dosage.
-
公开(公告)号：US20210049425A1
公开(公告)日：2021-02-18
申请号：US16976015
申请日：2019-02-28
申请人： VISIONGATE, INC.
发明人： Michael G. Meyer , Laimonis Kelbauskas , Rahul Katdare , Daniel J. Sussman , Timothy Bell , Alan C. Nelson
摘要： A method for a system and method for morphometric detection of malignancy associated change (MAC) is disclosed including the acts of obtaining a sample; imaging cells to produce 3D cell images for each cell; measuring a plurality of different structural biosignatures for each cell from its 3D cell image to produce feature data; analyzing the feature data by first using cancer case status as ground truth to supervise development of a classifier to test the degree to which the features discriminate between cells from normal or cancer patients; using the analyzed feature data to develop classifiers including, a first classifier to discriminate normal squamous cells from normal and cancer patients, a second classifier to discriminate normal macrophages from normal and cancer patients, and a third classifier to discriminate normal bronchial columnar cells from normal and cancer patients.
-
公开(公告)号：US11545237B2
公开(公告)日：2023-01-03
申请号：US16650304
申请日：2018-09-26
申请人： VISIONGATE, INC.
发明人： Michael G. Meyer , Daniel J. Sussman , Rahul Katdare , Laimonas Kelbauskas , Alan C. Nelson , Randall Mastrangelo
IPC分类号： G06T7/00 , G16B40/20 , G06T7/194 , G06T7/11 , G01N15/14 , G06K9/62 , G06V10/40 , G06V20/64 , G06V20/69 , G01N15/10
摘要： A classification training method for training classifiers adapted to identify specific mutations associated with different cancer including identifying driver mutations. First cells from mutation cell lines derived from conditions having the number of driver mutations are acquired and 3D image feature data from the number of first cells is identified. 3D cell imaging data from the number of first cells and from other malignant cells is generated, where cell imaging data includes a number of first individual cell images. A second set of 3D cell imaging data is generated from a set of normal cells where the number of driver mutations are expected to occur, where the second set of cell imaging data includes second individual cell images. Supervised learning is conducted based on cell line status as ground truth to generate a classifier.
-
公开(公告)号：US20210200987A1
公开(公告)日：2021-07-01
申请号：US16972552
申请日：2019-06-05
申请人： VISIONGATE, INC.
摘要： A method to develop one or more morphometric classifiers to identify a mismatch repair deficiency (MMRD). The method provides a non-invasive method of characterizing MMRD that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.
-
公开(公告)号：US20230050322A1
公开(公告)日：2023-02-16
申请号：US17968668
申请日：2022-10-18
申请人： VisionGate, Inc.
发明人： Michael G. Meyer , Daniel J. Sussman , Rahul Katdare , Laimonis Kelbauskas , Alan C. Nelson , Randall Mastrangelo
IPC分类号： G16B40/20 , G06T7/194 , G06T7/11 , G01N15/14 , G06K9/62 , G06T7/00 , G06V10/40 , G06V20/64 , G06V20/69
摘要： A classification training method for training classifiers adapted to identify specific mutations associated with different cancer including identifying driver mutations. First cells from mutation cell lines derived from conditions having the number of driver mutations are acquired and 3D image feature data from the number of first cells is identified. 3D cell imaging data from the number of first cells and from other malignant cells is generated, where cell imaging data includes a number of first individual cell images. A second set of 3D cell imaging data is generated from a set of normal cells where the number of driver mutations are expected to occur, where the second set of cell imaging data includes second individual cell images. Supervised learning is conducted based on cell line status as ground truth to generate a classifier.
-
公开(公告)号：US11551043B2
公开(公告)日：2023-01-10
申请号：US16976015
申请日：2019-02-28
申请人： VISIONGATE, INC.
发明人： Michael G. Meyer , Laimonas Kelbauskas , Rahul Katdare , Daniel J. Sussman , Timothy Bell , Alan C. Nelson
摘要： A method for a system and method for morphometric detection of malignancy associated change (MAC) is disclosed including the acts of obtaining a sample; imaging cells to produce 3D cell images for each cell; measuring a plurality of different structural biosignatures for each cell from its 3D cell image to produce feature data; analyzing the feature data by first using cancer case status as ground truth to supervise development of a classifier to test the degree to which the features discriminate between cells from normal or cancer patients; using the analyzed feature data to develop classifiers including, a first classifier to discriminate normal squamous cells from normal and cancer patients, a second classifier to discriminate normal macrophages from normal and cancer patients, and a third classifier to discriminate normal bronchial columnar cells from normal and cancer patients.
-
8.发明申请公开(公告)号：US20170140533A1
公开(公告)日：2017-05-18
申请号：US15403940
申请日：2017-01-11
申请人： VISIONGATE, INC.
发明人： Alan C. Nelson , Michael G. Meyer
IPC分类号： G06T7/00 , A61K39/00 , A61K31/5578 , A61K31/167 , G01N21/77 , C07K19/00 , G06K9/62 , G06T7/11 , G01N15/14 , G01N33/483 , A61K31/593
CPC分类号： G06T7/0012 , A61K31/167 , A61K31/5578 , A61K31/593 , G01N15/14 , G01N15/1434 , G01N15/1468 , G01N33/4833 , G01N2015/1006 , G01N2015/1445 , G06K9/00147 , G06K9/00201 , G06T2207/10101 , G06T2207/30024
摘要： A method of treating a malignancy in a human subject by analyzing pseudo-projection images of cells obtained from a sputum specimen obtained from a subject employs a biological specimen classifier that identifies cells from the sputum specimen as normal or abnormal. If abnormal cells are detected, then the abnormal cells are further classified as dysplastic or cancerous. If the cells are classified as dysplastic, then an immunomodulating agent is administered to the subject over a predetermined time period designed to achieve a therapeutic dosage.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.015 秒)